ClinicalTrials.gg
TerminatedNCT04752332eMonarcHERUpdated Jul 15, 2025Results posted

A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

A Phase 3 interventional study of Abemaciclib and Standard Adjuvant ET in Breast Neoplasms, sponsored by Eli Lilly and Company. Terminated at 115 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Why this study was terminated
Study is terminated due to inability to enroll study participants

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
29th of 55
111 · median 120
Started
2021
with 6 others
Phase 3
11 of 55
2 open now
Registered
33rd of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 29th largest by enrollment, is one of 7 that started in 2021, is one of 11 in phase 3, and was the 33rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after surgery. Participants must have breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+). Your participation could last up to 10 years depending on how you and your tumor respond.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have confirmed HR+, + early invasive breast cancer without evidence of disease recurrence or distant
  • Have undergone definitive surgery of the primary breast tumor(s)
  • Have tumor tissue from breast (preferred) or lymph node
  • Have received a minimum of four cycles of chemotherapy in either the or adjuvant setting per standard of care
  • Have completed approximately nine to 20 months of standard HER2-targeted therapy (neoadjuvant/adjuvant combined duration)
  • Have received one of the following eligible HER2-targeted adjuvant regimens AND be randomized within 12 weeks of completing the regimen:

    • For participants treated with neoadjuvant therapy and HER2-targeted therapy: A minimum of 4 cycles of T-DM1 in the adjuvant setting. NOTE: Participants may have received up to approximately 6 cycles of adjuvant trastuzumab prior to initiation of T-DM1. Additionally, participants may have switched to trastuzumab-based therapy (monotherapy or in combination with other HER2-targeted therapies) after 4 cycles of T-DM1
    • For participants who had definitive surgery prior to systemic therapy, a minimum of 4 cycles of adjuvant pertuzumab with trastuzumab.
  • Have high risk disease, defined by one of the following criteria:

    • Those who received neoadjuvant chemotherapy along with HER2-targeted treatment must have:

      • residual disease in at least one axillary lymph node, or
      • a residual tumor ≥ 5 cm, or
      • a residual tumor of any size that has direct extension to the chest wall and/or skin (ulceration or skin nodules).
    • Those who had definitive surgery prior to systemic therapy and completed adjuvant chemotherapy along with HER2-targeted therapies (trastuzumab and pertuzumab) must have

      • tumor involvement in ≥4 ipsilateral axillary lymph nodes, or
      • tumor involvement in 1 to 3 ipsilateral axillary lymph node(s) and histological Grade 3, or
      • primary invasive tumor size of ≥ 5 cm on pathological evaluation.

Exclusion criteria

Exclusion Criteria:

  • Have breast cancer with any of the following features:

    • Disease recurrence or distant disease (including contralateral axillary lymph nodes)
    • Pathological complete response from any prior early breast cancer treatments. Participants are required to have residual primary tumor and/or lymph node disease at the time of definitive surgery as indicated in inclusion criteria.
    • Inflammatory breast cancer
  • Have other medical conditions including:

    • Previous breast cancer (Exceptions: Ipsilateral ductal carcinoma in situ [DCIS] treated by locoregional therapy alone ≥5 years ago; contralateral DCIS treated by locoregional therapy at any time)
    • Other cancer being treated and/or not in complete remission within the last 5 years (Exceptions: Appropriately treated non-melanomatous skin cancer or carcinoma in situ of cervix, bladder, or colon)
    • Females who are pregnant or lactating
    • History of venous thromboembolism
    • Other serious medical conditions
  • Have previously received treatment with:

    • Any cyclin-dependent kinase (CDK)4 and CDK6 inhibitor
    • Prior treatment with immunotherapy, tucatinib, neratinib, any directed therapy, or T-DXd (DS8201) for treatment of breast cancer
    • Endocrine therapy (ET) (i.e., tamoxifen, raloxifene or aromatase inhibitor) for breast cancer prevention (without diagnosis of breast cancer)
    • Additional chemotherapy, anti-cancer ET, or HER2-targeted therapy beyond standard of care at study enrollment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    150 mg Abemaciclib + Endocrine Therapy (ET)

    Participants received 150 milligrams (mg) of abemaciclib administered twice daily (BID) orally along with standard adjuvant endocrine therapy (ET).

    Drug: Abemaciclib · Drug: Standard Adjuvant ET

  • Active comparator
    Placebo + ET

    Participants received placebo administered BID orally along with standard adjuvant ET.

    Drug: Standard Adjuvant ET · Drug: Placebo

Interventions

  • Administered orally.

    Also known as: LY2835219

  • DrugStandard Adjuvant ET

    Administered according to label instructions.

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Invasive Disease Free Survival (IDFS)

    IDFS, as defined by the STEEP System, is measured from the date of randomization to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

    Time frame: Randomization to Recurrence or Death from Any Cause (up to 890 days)

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization until death from any cause. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

    Time frame: Randomization to Death from Any Cause (up to 890 days)

  2. Distant Relapse-Free Survival (DRFS)

    DRFS is defined as the time from randomization to distant recurrence or death from any cause, whichever occurs first. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

    Time frame: Randomization to Distant Recurrence or Death from Any Cause (up to 890 days)

  3. Percentage of Participants With Central Nervous System (CNS) Metastases as First Site of Disease Recurrence

    Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

    Time frame: Randomization to Distant Recurrence or Death from Any Cause (up to 890 days)

  4. Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Scale Score

    The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation will be applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

    Time frame: Cycle 1 up to 390 days

  5. Change From Baseline in the EuroQOL 5 Dimension 5 Level (EQ-5D 5L) Index Score

    The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. Five dimensions of health status are each assessed with 5 response options and scored as a composite index which are anchored on a scale of 0 to 1 with a higher score representing better health status. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

    Time frame: Cycle 1 up to 390 days

  6. Pharmacokinetics (PK): Mean Steady State Concentrations of Abemaciclib

    Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

    Time frame: Day 1 of Cycles 1-3 (Cycle = 28 days)

07

Results

Posted Jul 15, 2025
Limitations and caveats
The study was terminated early due to inability to enroll study participants.

Participant flow

The study was terminated early due to inability to enroll study participants. Data was not collected after termination and outcome measures were not assessed.

Participant flow — Overall Study
Milestone150 mg Abemaciclib + Endocrine Therapy (ET)Placebo + ET
Started5556
Received at least one dose of study drug5556
Completed250
Not completed3056
Withdrew: Adverse event31
Withdrew: Disease relapse10
Withdrew: Non-compliance with study drug20
Withdrew: Physician decision21
Withdrew: Protocol violation11
Withdrew: Study terminated by irb/erb02
Withdrew: Study terminated by sponsor1048
Withdrew: Withdrawal by subject113

Outcome measures

PrimaryInvasive Disease Free Survival (IDFS)

IDFS, as defined by the STEEP System, is measured from the date of randomization to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

Time frame:
Randomization to Recurrence or Death from Any Cause (up to 890 days)

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

OS is defined as the time from randomization until death from any cause. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

Time frame:
Randomization to Death from Any Cause (up to 890 days)

No measurements were reported for this outcome.

SecondaryDistant Relapse-Free Survival (DRFS)

DRFS is defined as the time from randomization to distant recurrence or death from any cause, whichever occurs first. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

Time frame:
Randomization to Distant Recurrence or Death from Any Cause (up to 890 days)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Central Nervous System (CNS) Metastases as First Site of Disease Recurrence

Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

Time frame:
Randomization to Distant Recurrence or Death from Any Cause (up to 890 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Scale Score

The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation will be applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

Time frame:
Cycle 1 up to 390 days

No measurements were reported for this outcome.

SecondaryChange From Baseline in the EuroQOL 5 Dimension 5 Level (EQ-5D 5L) Index Score

The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. Five dimensions of health status are each assessed with 5 response options and scored as a composite index which are anchored on a scale of 0 to 1 with a higher score representing better health status. Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

Time frame:
Cycle 1 up to 390 days

No measurements were reported for this outcome.

SecondaryPharmacokinetics (PK): Mean Steady State Concentrations of Abemaciclib

Study was terminated early. Data was not collected for this outcome and outcome measures were not assessed.

Time frame:
Day 1 of Cycles 1-3 (Cycle = 28 days)

No measurements were reported for this outcome.

Adverse events

Collected over Baseline Up To 890 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
150 mg Abemaciclib + ET0/55 (0%)6/55 (10.9%)53/55 (96.4%)
Placebo + ET0/56 (0%)2/56 (3.6%)40/56 (71.4%)
Most frequent serious events
Most frequent serious events
Event150 mg Abemaciclib + ETPlacebo + ET
NeutropeniaBlood and lymphatic system disorders1/550/56
Anal abscessInfections and infestations1/550/56
Covid-19Infections and infestations1/550/56
Radius fractureInjury, poisoning and procedural complications1/551/56
Alanine aminotransferase increasedInvestigations1/550/56
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/550/56
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/541/56
Most frequent other events
Showing 10 of 34
Most frequent other events
Event150 mg Abemaciclib + ETPlacebo + ET
DiarrhoeaGastrointestinal disorders44/555/56
NeutropeniaBlood and lymphatic system disorders28/554/56
LeukopeniaBlood and lymphatic system disorders17/553/56
NauseaGastrointestinal disorders17/558/56
FatigueGeneral disorders16/556/56
AnaemiaBlood and lymphatic system disorders13/551/56
Covid-19Infections and infestations13/558/56
ThrombocytopeniaBlood and lymphatic system disorders12/550/56
Abdominal painGastrointestinal disorders12/556/56
VomitingGastrointestinal disorders11/551/56

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)150 mg Abemaciclib + ETPlacebo + ETTotal
Mean48.60 ± 11.7649.70 ± 11.1749.20 ± 11.43
Sex: Female, Male
Sex: Female, Male(Participants)150 mg Abemaciclib + ETPlacebo + ETTotal
Female5456110
Male101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)150 mg Abemaciclib + ETPlacebo + ETTotal
Hispanic or Latino91221
Not Hispanic or Latino444185
Unknown or Not Reported235
Race (NIH/OMB)
Race (NIH/OMB)(Participants)150 mg Abemaciclib + ETPlacebo + ETTotal
American Indian or Alaska Native011
Asian262349
Native Hawaiian or Other Pacific Islander000
Black or African American123
White272956
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)150 mg Abemaciclib + ETPlacebo + ETTotal
Argentina459
Australia112
Austria011
Belgium224
Brazil336
China121527
France202
Germany213
Greece448
Hungary101
Israel101
Italy112
Japan7310
Mexico112
South Korea426
Spain358
Switzerland022
Taiwan134
United Kingdom145
United States538
08

Study locations

115 sites
  • Palo Verde Cancer Specialists
    Glendale, Arizona 85304, United States
  • TRIO-US (Translational Research in Oncology-US)
    Los Angeles, California 90024, United States
  • Millennium Oncology - Hollywood
    Hollywood, Florida 33024, United States
  • Florida Cancer Specialists - North
    St. Petersburg, Florida 33705, United States
  • Mt. Sinai Hospital PRiSMS
    Chicago, Illinois 60608, United States
  • Cornell-Beshore Cancer Institute
    Joplin, Missouri 64804, United States
  • The Valley Hospital
    Ridgewood, New Jersey 07450, United States
  • Sarah Cannon Research Institute SCRI
    Nashville, Tennessee 37203, United States
  • Texas Oncology - Medical City Dallas
    Dallas, Texas 75230, United States
  • Northwest Cancer Specialists PC
    The Woodlands, Texas 77380, United States
  • Texas Oncology - Medical City Dallas
    The Woodlands, Texas 77380, United States
  • US Oncology
    The Woodlands, Texas 77380, United States
  • USO-Southern Cancer Center, P.C.
    The Woodlands, Texas 77380, United States
  • Instituto de Investigaciones Clínicas Mar del Plata
    Mar del Plata, Buenos Aires 7600, Argentina
  • Fundación Cenit Para La Investigación En Neurociencias
    CABA, Buenos Aires F.D. 1125, Argentina
  • Centro Medico Privado CEMAIC
    Capital, Córdoba Province X5008HHW, Argentina
  • Centro Medico San Roque
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Fundación CORI para la Investigación y Prevención del Cáncer
    La Rioja, F5300COE, Argentina
  • Sanatorio Parque
    Salta, 4400, Argentina
  • CER San Juan
    San Juan, 5400, Argentina
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Medizinische Universität Wien
    Vienna, State of Vienna 1090, Austria
  • Ordensklinikum Linz
    Linz, Upper Austria 4020, Austria
  • AZ Maria Middelares
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Clinique Saint Pierre
    Ottignies, Wallonne, Région 1340, Belgium
  • Jan Yperman ziekenhuis
    Ieper, West-Vlaanderen 8900, Belgium
  • AZ Groeninge Campus Kennedylaan
    Kortrijk, West-Vlaanderen 8500, Belgium
  • Instituto de Educação, Pesquisa e Gestão em Saúde
    Rio de Janeiro, 22775-001, Brazil
  • NotreDame Intermedica Saude S.A
    São Paulo, 01229-010, Brazil
  • Núcleo de Pesquisa Clínica da Rede São Camilo
    São Paulo, 04014-002, Brazil
  • Instituto D'Or de Pesquisa e Ensino (IDOR)
    São Paulo, 04543-000, Brazil
  • Instituto de Ensino e Pesquisa São Lucas
    São Paulo, 1236030, Brazil
  • Afflilated Hospital of Bengbu Medical College
    Bengbu, Anhui 233004, China
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100034, China
  • Beijing Cancer hospital
    Beijing, Beijing Municipality 100142, China
  • Fujian Medical University Union Hospital-1 Bingfanglou
    Fuzhou Fujian, Fujian 350001, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
  • Hainan Cancer Hospital
    Haikou, Hainan 570000, China
  • Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210000, China
  • The Third Hospital of Nanchang
    Nanchang, Jiangxi 330009, China
  • The Second Hospital of Jilin University
    Changchun, Jilin, China
  • LinYi Cancer Hospital
    Linyi, Shandong 276000, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Sichuan Cancer hospital
    Chengdu, Sichuan 610042, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality, China
  • Xinjiang Medical University Cancer Hospital - Urumqi
    Ürümqi, Xinjiang 830011, China
  • The First Affiliated Hospital, Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • The First People's Hospital of Hangzhou
    Hangzhou, Zhejiang 310006, China
  • CHU Besançon
    Besançon, Doubs 25000, France
  • Institut de Cancérologie de Lorraine Alexis Vautrin
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54519, France
  • Centre Oscar Lambret
    Lille, Nord 59020, France
  • Clinique Victor Hugo Le Mans
    Le Mans, Pays de la Loire Region 72000, France
  • Klinikum Ludwigsburg
    Ludwigsburg, Baden-Wurttemberg 71640, Germany
  • Universitätsmedizin Mannheim
    Mannheim, Baden-Wurttemberg 68135, Germany
  • Universitaetsklinikum Ulm
    Ulm, Baden-Wurttemberg 89075, Germany
  • St. Vincenz-Krankenhaus Frauen- und Kinderklinik
    Paderborn, North Rhine-Westphalia 33098, Germany
  • Alexandra Hospital
    Athens, Attikí 115 28, Greece
  • General Oncology Hospital of Kifissia "Agioi Anargiroi"
    Nea Kifissia, Attikí 14564, Greece
  • Euromedica General Clinic of Thessaloniki
    Thessaloniki, Thessaloníki 546 45, Greece
  • European Interbalkan Medical Center
    Thessaloniki, 570 01, Greece
  • Petz Aladar Egyetemi Oktato Korhaz
    Győr, Győr-Moson-Sopron 9024, Hungary
  • Sourasky Medical Center
    Tel Aviv, Tell Abīb 6423906, Israel
  • Ospedale San Giovanni Moscati
    Statte, Taranto 74100, Italy
  • Ospedale Mater Salutis
    Legnago, Verona 37045, Italy
  • Ospedale Generale Provinciale Macerata
    Province of Macerata, 62100, Italy
  • Nagoya City University Hospital
    Nagoya, Aichi-ken 467-8602, Japan
  • Chiba cancer center
    Chiba, Chiba 260-8717, Japan
  • National Hospital Organization Shikoku Cancer Center
    Matsuyama, Ehime 791-0280, Japan
  • Gunma Prefectural Cancer Center
    Ōta, Gunma 373-0828, Japan
  • Tsukuba University Hospital
    Tsukuba, Ibaraki 305-8576, Japan
  • Ishikawa Prefectural Central Hospital
    Kanazawa, Ishikawa-ken 920-8201, Japan
  • St. Marianna University Hospital
    Kawasaki, Kanagawa 216-8511, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • Japanese Foundation for Cancer Research
    Koto, Tokyo 135-8550, Japan
  • Showa University Hospital
    Shinagawa, Tokyo 142-8555, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, 811-1395, Japan
  • Hiroshima University Hospital
    Hiroshima, 734-8551, Japan
  • Sagara Hospital
    Kagoshima, 892-0833, Japan
  • Kumamoto Shinto General Hospital
    Kumamoto, 862-8655, Japan
  • National Hospital Organization Osaka Medical Center
    Osaka, 540-0006, Japan
  • Osaka International Cancer Institute
    Osaka, 541-8567, Japan
  • Shizuoka General Hospital
    Shizuoka, 420-8527, Japan
  • St. Luke's International Hospital
    Tokyo, 104-8560, Japan
  • Centro Oncológico Internacional (COI)
    Guadalajara, Jalisco 45647, Mexico
  • Grupo Medico Camino Sc
    Mexico City, Mexico City 3310, Mexico
  • Inha University Hospital
    Incheon, Incheon-gwangyeoksi [Incheon] 22332, South Korea
  • Seoul National University Bundang Hospital
    Seongnam, Kyǒnggi-do 13620, South Korea
  • CHA Bundang Medical Center, CHA University
    Seongnam-si, Kyǒnggi-do 13496, South Korea
  • Korea University Anam Hospital
    Seoul, Seoul-teukbyeolsi [Seoul] 2841, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, Seoul-teukbyeolsi [Seoul] 3722, South Korea
  • CHUAC-Hospital Teresa Herrera
    A Coruña, A Coruña [La Coruña] 15006, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Madrid, Comunidad de 28041, Spain
  • H.R.U Málaga - Hospital Materno-infantil
    Málaga, Málaga 29011, Spain

Showing the first 100 of 115 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Jun 2024, 37 months.

Results were first posted in Jul 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2021
First posted
Feb 12, 2021
StartActual
May 10, 2021
Primary completionActual
Jun 26, 2024
CompletionActual
Jun 26, 2024
Results first posted
Jul 15, 2025
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04752332
Responsible party
Sponsor
First posted
Feb 12, 2021
Start date
May 10, 2021
Primary completion
Jun 26, 2024
Completion
Jun 26, 2024
Results posted
Jul 15, 2025
Last update
Jul 15, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion